| Project/Area Number |
11670522
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
YOKOYAMA Yoshifumi Nagoya City Univ. Medical School, Associate Professor, 医学部, 助教授 (00145723)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
JOH Takashi Nagoya City Univ. Medical School, Associate Professor, 医学部, 助教授 (30231369)
TOCHIKUBO Kunio Nagoya City Univ. Medical School, Professor, 医学部, 教授 (30079991)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 2000: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1999: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | mucosal immunity / Helicobacter pylori / Choleratoxin B-subunit |
|---|
| Research Abstract |
Background : Choleratoxin (CT) is often used as an experimental mucosal immuno-adjuvant but possesses the strong toxicity to human intestinal mucosa. We have previously reported that unadulterated recombinant B subunit of CT (rCTB) was obtained from Bacillus brevis carrying CTB gene-inserted plasmid pNU212. This study was performed to investigate mucosal and systemic immunoadjuvant activities of very pure rCTB against H.pylori by oral and nasal immunizations.
Methods : Mice were immunized with H.pylori-sonicate plus rCTB on days 0, 7, 14 and 21 via oral or nasal route and sacrificed on day 42. Blood and lavage fluids of the stomach and the small and large intestines were collected. H.pylori/-specific IgG and IgA antibody titers in serum and lavage fluids were estimated using ELISA.
Results : In both nasal and oral immunizations, co-administration of CTB demonstrated significant adjuvant properties for stimulating systemic and mucosal IgG and IgA immune responses to H.pylori.
Conclusion : In conclusion, these results demonstrated that genuine rCTB has significant adjuvant properties for stimulating systemic and mucosal IgG and IgA responses to non-coupled H.pylori-antigens after oral and nasal coimmunizations, indicating that rCTB is one of the candidates as a nontoxic adjuvant for mucosal vaccines against H.pylori.
|
